NAMPT haploinsufficiency is a therapeutic vulnerability to NAMPT inhibition in -7/-7q MDS

Nemo Ikonen,[1,2] Tanja Ruokoranta,[1,3] Salla Hyyppä,[1] Ella Sinervuori,[1,2] Juho J. Miettinen,[1,2] Joseph Saad,[1,2] Markus Vähä-Koskela,[1,2] and Caroline A. Heckman[1,2]

[1]Institute for Molecular Medicine Finland - FIMM, Helsinki Institute of Life Science, University of Helsinki, Finland

[2]iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Finland

[3]Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Correspondence: Caroline Heckman, PhD, Institute for Molecular Medicine Finland, University of Helsinki, Tukholmankatu 8 (P.O. Box 20), FI-00290 Helsinki, Finland, Telephone: +358 50 4156769, Email: caroline.heckman@helsinki.fi

Text word count: 719 / 700   **Figures:** 2/2

References: 20 / 12   **Supplement:** Yes

Abstract

Chromosome 7 abnormalities -7 and -7q define a high-risk subset of myelodysplastic syndromes (MDS) with poor prognosis. The *NAMPT* gene, located at 7q22.3, encodes a rate limiting enzyme (nicotinamide phosphoribosyl transferase) in the NAD+ salvage pathway. Several inhibitors of NAMPT have been developed but their activity in MDS has

not been previously described. In this study we investigated if MDS myeloblasts are

susceptible to NAMPT inhibition. We show that primary bone marrow cells from patients

with -7/-7q MDS exhibit strong and select sensitivity. Bulk viability assays and single cell,

multiparametric flow cytometry confirmed enhanced NAMPT inhibitor sensitivity across

leukemic cell populations, especially CD34+CD38+ blasts from -7/-7q MDS samples

compared to non -7/-7q MDS and healthy donor bone marrow cells. The NAMPT inhibitor

KPT-9274 combined with BCL2 inhibitor venetoclax was particularly effective at targeting

MDS blasts compared to NAMPT inhibition alone. MDS samples with -7/-7q also showed

significantly lower *NAMPT* expression compared to the non -7/-7q samples, indicative of

haploinsufficient gene expression profile. In conclusion, these findings support *NAMPT*

haploinsufficiency as a vulnerability and as biomarker for NAMPT inhibitor activity in -7/-

7q MDS.

Research letter

Monosomy 7 and deletion of the q arm of chromosome 7 (-7/-7q) are recurrent alterations in myelodysplastic syndromes (MDS) present in approximately 10% of patients, and are associated with poor prognosis, shorter survival, and increased risk of progression to acute myeloid leukemia (AML) (1,2). Nicotinamide phosphoribosyl transferase (NAMPT), encoded by the *NAMPT* gene at chromosome 7q22.3, is the rate limiting enzyme in the nicotinamide adenine dinucleotide (NAD+) salvage pathway (3). NAMPT inhibitors have shown good efficacy in preclinical studies of hematological malignancies as they effectively target cancer cell metabolism by blocking the salvage pathway which leads to NAD+ depletion and cell death (4–7). Previous studies have shown that AML blasts with -7/-7q are exceptionally sensitive to NAMPT inhibitors, with the sensitivity caused by *NAMPT* gene haploinsufficiency as a result of -7/-7q (8,9). The objective of this study was to investigate whether MDS blasts with -7/-7q are similarly susceptible to NAMPT inhibition, and if *NAMPT* haploinsufficiency could be a biomarker for NAMPT inhibitor activity in MDS.

The patient sample cohort is described in **Supplemental Table 1,** and the methods are described in full in the **Supplemental Material** and illustrated in **Figure 1A.** We first assessed the bulk cell viability-based drug sensitivity screening results from bone marrow (BM) cell samples collected from patients with MDS and compared it to data from BM mononuclear cells (MNCs) from healthy donors that were published previously (8,10). MDS and healthy donor BM-MNCs were incubated with the NAMPT inhibitor daporinad for 72 hours, and cell viability was measured using the CellTiter-Glo (CTG) and CellTox Green (CTxG) assays. Dose response curves (**Figure 1B–C**) were summarized as drug

sensitivity scores (DSS) (**Figure 1D–E**, **Supplemental Tables 2–3**). Overall, MDS

samples were significantly more sensitive to NAMPT inhibition compared to the healthy

donor samples in the CTG assay (**Supplemental Figure 1A**), indicative of an actionable

therapeutic window and in line with previous studies in AML (4,5,8,11). The sample

carrying -7/-7q was found to be the most responsive sample to NAMPT inhibition (**Figure**

1D). A similar trend was observed in the CTxG assay, with the -7/-7q MDS sample being

the most sensitive, but there was no significant difference between MDS and healthy

donor samples (**Figure 1E, Supplemental Figure 1B**). To assess if the -7/-7q MDS

samples express less *NAMPT* due to *NAMPT* gene haploinsufficiency, we analyzed the

gene expression in CD34+CD38- cells which showed that samples with -7/-7q had

significantly lower *NAMPT* expression, indicating a haploinsufficient gene expression

profile (**Figure 1F**, **Supplemental Table 4**).

To investigate NAMPT inhibitor activity in different cell subpopulations, we performed flow

cytometry-based drug sensitivity analysis. MDS BM-MNCs were incubated with the

NAMPT inhibitors daporinad and KPT-9274 for 72 hours (**Supplemental Table 5**) and

subsequently stained with an antibody panel (**Supplemental Table 6**). We observed that

NAMPT inhibitors effectively target the different myeloblast populations in MDS samples

and that CD34+, CD117+, CD34+CD117+, CD34+CD38- and CD34+CD38+ blasts from

-7/-7q MDS were significantly more sensitive to NAMPT inhibition by daporinad compared

to non -7/-7q MDS blasts (**Figure 2A, Supplemental Figure 2**, **Supplemental Table 7**).

Similar trends were observed for KPT-9274, however, the results were not significant

(**Figure 2B**). Additionally, CD34+CD38+ blasts were more sensitive to daporinad and

KPT-9274 than CD3+ T lymphocyte cells representing a healthy cell population control

and CD14+ monocytic cell population in -7/-7q samples (**Supplemental Figure 3A-B**).

These results indicate that the cell populations with a leukemic phenotype, particularly

CD34+CD38+, are sensitive to NAMPT inhibition.

Next, we assessed KPT-9274 efficacy with three different clinically relevant drug

combinations: venetoclax, azacitidine and cytarabine. We observed that the combination

of KPT-9274 and venetoclax was significantly more cytotoxic towards CD34+CD38- cells

in samples with -7/-7q compared to KPT-9274 alone (**Figure 2C**), and the combination

was significantly more cytotoxic in -7/-7q compared to non -7/-7q samples (**Figure 2C**).

The addition of azacitidine or cytarabine did not significantly decrease the cell viability

(**Supplemental Table 8**, **Supplemental Figure 3C–D**).

The data from this study demonstrate that NAMPT inhibitors are highly active in -7/-7q

MDS *ex vivo* and establish *NAMPT* haploinsufficiency as a vulnerability and biomarker

for NAMPT inhibitor activity. The findings suggest that patients with MDS, especially those

with -7/-7q, could benefit from NAMPT inhibitors, and support expanded investigations,

including clinical evaluation, of NAMPT inhibitors in high-risk MDS.

Declarations

Ethics approval and consent to participate

Bone marrow (BM) or peripheral blood (PB) samples were collected from patients with

MDS after informed consent using protocols approved by the Institutional Review Board

at the Helsinki University Hospital (permit numbers 239/13/03/00/2010 and

303/13/03/01/2011, Helsinki University Hospital Ethics Committee) in compliance with the Declaration of Helsinki.

Consent for publication

Not applicable

Availability of data and materials: The data generated or analyzed during this study are included in this manuscript and its supplementary files. RNA counts data have been deposited to Zenodo: link and DOI will be provided following manuscript acceptance. All other relevant data to the current study are available from the corresponding author (Caroline Heckman, caroline.heckman@helsinki.fi) on reasonable request.

Competing interest: C.A.H. has received research funding for unrelated work from Oncopeptides, IMI2 projects HARMONY and HARMONY PLUS, WNTResearch, Orion, Kronos Bio, Novartis, Celgene, and Zentalis Pharmaceuticals; has been awarded honoraria from Amgen and consultancy fees from Autolus. M.V.-K has received research funding from Immunocore UK for unrelated work. Other authors declare no conflicts of interest.

Funding: This work was supported by the University of Helsinki, Cancer Foundation Finland, the Academy of Finland (grants 334781, 1357686, 1320185) (C.A.H.), the Sigrid Jusélius Foundation, Veritautien tutkimussäätiö (N.I.), Ida Montin Foundation (N.I.), the Finnish Cultural Foundation (N.I.), Orion Research Foundation (N.I.), Finnish Hematology Association (N.I.) and Instrumentarium Science Foundation (N.I.).

Authors' contributions: N.I., T.R., S.H., E.S., J.M. and J.S. planned and conducted experiments. N.I. analyzed and interpreted the data. N.I., and C.A.H wrote the

manuscript. M.V.-K. and C.A.H. provided leadership and funding. All authors read and

approved the manuscript.

Acknowledgements: The authors thank the patients and clinics who made this study

possible. The authors also thank the Finnish Hematology Registry and Clinical Biobank

(FHRB) for providing the samples and clinical information. Instruments, drug plate

preparation and part of the flow cytometry analysis were carried out by the FIMM High

Throughput Biomedicine Unit, and library preparation and RNA sequencing were

performed by Biomedicum Functional Genomics Unit and FIMM Genomics NGS

Sequencing unit, which all are hosted by the University of Helsinki and supported by

HiLIFE and Biocenter Finland. Cell sorting and analysis were performed at the HiLife Flow

Cytometry Unit, University of Helsinki. N.I. is a Ph.D. candidate at the University of

Helsinki. This work is submitted in partial fulfillment of the requirement for the Ph.D. The

authors would like to express gratitude to Minna Suvela and Alun Parsons for their role in

processing the samples for the study and to Natalia Mokrzecka for her help with the flow

cytometry.

143 References

1. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al.
New insights into the prognostic impact of the karyotype in MDS and correlation with
subtypes: evidence from a core dataset of 2124 patients. Blood. 2007 Dec
15;110(13):4385–95. doi:10.1182/blood-2007-03-082404

2. Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J, et al. New
Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes
(MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an
International Database Merge. J Clin Oncol. 2012 Mar 10;30(8):820–9.
doi:10.1200/JCO.2011.35.6394 PubMed PMID: 22331955; PubMed Central PMCID:
PMC4874200.

3.   Revollo JR, Grimm AA, Imai S ichiro. The NAD Biosynthesis Pathway Mediated by
Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells*. J
Biol Chem. 2004 Dec 3;279(49):50754–63. doi:10.1074/jbc.M408388200

4.   Nahimana A, Attinger A, Aubry D, Greaney P, Ireson C, Thougaard AV, et al. The
NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic
malignancies. Blood. 2009 Apr 2;113(14):3276–86. doi:10.1182/blood-2008-08-173369
PubMed PMID: 19196867.

5.   Mitchell SR, Larkin K, Grieselhuber NR, Lai TH, Cannon M, Orwick S, et al.
Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv. 2019
Feb   12;3(3):242–55.   doi:10.1182/bloodadvances.2018024182   PubMed   PMID:
30692102; PubMed Central PMCID: PMC6373756.

6.   Korotchkina L, Kazyulkin D, Komarov PG, Polinsky A, Andrianova EL, Joshi S, et
al. OT-82, a novel anticancer drug candidate that targets the strong dependence of
hematological malignancies on NAD biosynthesis. Leukemia. 2020 Jul;34(7):1828–39.
doi:10.1038/s41375-019-0692-5

7.   Åleskog A, Bashir-Hassan S, Hovstadius P, Kristensen J, Höglund M, Tholander
B, et al. Activity of CHS 828 in primary cultures of human hematological and solid tumors
in vitro. Anticancer Drugs. 2001 Nov;12(10):821.

8.   Eldfors S, Saad J, Ikonen N, Malani D, Vähä-Koskela M, Gjertsen BT, et al.
Monosomy   7/del(7q)   cause   sensitivity   to   inhibitors   of   nicotinamide
phosphoribosyltransferase   in   acute   myeloid   leukemia.   Blood   Adv.   2024   Mar
27;8(7):1621–33. doi:10.1182/bloodadvances.2023010435

9.   Senagolage MD, Blaylock HZ, Khan S, Skuli SJ, Carroll MP, McNerney ME.
NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk
myeloid malignancies with TP53 inactivation. Blood Neoplasia. 2025 Aug 20;2(3):100119.
doi:10.1016/j.bneo.2025.100119

10.   Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, et al. Implementing
a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer
Discov. 2022 Feb;12(2):388–401. doi:10.1158/2159-8290.CD-21-0410 PubMed PMID:
34789538; PubMed Central PMCID: PMC9762335.

11.   Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, et al.
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid
Leukemia   Stem   Cells.   Cell   Stem   Cell.   2020   Nov   5;27(5):748-764.e4.
doi:10.1016/j.stem.2020.07.021 PubMed PMID: 32822582; PubMed Central PMCID:
PMC7655603.

189
190

Figure legends

Figure 1. MDS samples are sensitive to NAMPT inhibition. A) Illustration of the experimental workflow. Created with Biorender.com. B) Dose response curves for CellTiter-Glo-based and C) CellTox-Green-based bulk cell viability assays. Samples were treated with daporinad in 5 concentrations for 72 hours. D) Daporinad drug sensitivity score (DSS) values for MDS (n=6) and healthy (n=14) samples for CellTiter-Glo assay. Higher DSS indicates greater sensitivity. Data for healthy samples were summarized as one curve with standard deviations. E) Daporinad DSS values for MDS (n=7) and healthy (n=5) samples for CellTox Green assay. Data for healthy samples (n=5) were summarized as one score with standard deviation. F) *NAMPT* gene expression z-scores were compared between -7/-7q (n=5) and non -7/-7q MDS samples (n=25) using a the two-sample t-test. Gene expression profiles were analyzed from sorted CD34+CD38- cells.

Figure 2. Flow cytometry-based drug sensitivity screening shows that MDS samples with -7/-7q are highly sensitive to NAMPT inhibition. Drug sensitivity scores for the different cell populations for A) daporinad and B) KPT-9274. MDS samples with (n=8) and without (n=12) -7/-7q were incubated with the inhibitors for 72 hours and dose response curves were summarized as DSS values. Higher DSS indicates greater sensitivity. Samples with -7/-7q were compared to those without -7/-7q using a two-sample t-test. C) Comparison of cell viability between single agents and the combination of 1000 nM of KPT-9274 and 10 nM of venetoclax in CD34+CD38- cells in -7/-7q (n=5) and non -7/-7q (n=5) MDS samples. Samples were treated with the inhibitors for 72 hours, after which the cells were stained with detection antibodies to separate different cell types.

213 Comparisons were done using a two-sample t-test and *P* values were adjusted using the

214 Benjamini-Hochberg method.

Figure 1.

Figure 2.